{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Lifestance Health Group, Inc.
Lifestance Health Group Hits New 52-Week High of $11.68
Lifestance Health Group, Inc. has achieved a new 52-week high, reflecting strong performance with a 116.45% return over the past year. The company reported significant net profit growth and has maintained positive results for eight consecutive quarters, showcasing its operational efficiency and solid financial standing.
Lifestance Health Group Hits New 52-Week High of $11.48
Lifestance Health Group, Inc. has achieved a new 52-week high, reflecting its strong performance with a significant increase over the past year. The company has reported impressive financial metrics, including substantial net profit growth and consistent positive results over eight quarters, positioning it favorably within the Pharmaceuticals & Biotechnology sector.
Lifestance Health Group Hits New 52-Week High of $10.89
Lifestance Health Group, Inc. has achieved a new 52-week high, reflecting its strong performance with a notable return over the past year. The company reported substantial net profit growth and positive results for eight consecutive quarters, alongside impressive operating cash flow and a favorable debt-to-equity ratio.
Lifestance Health Group Hits New 52-Week High of $10.62
Lifestance Health Group, Inc. has achieved a new 52-week high, reflecting strong performance with a 93.27% increase over the past year. The company reported significant growth in net profit and has delivered positive results for eight consecutive quarters, supported by robust financial metrics and a solid market position.
Lifestance Health Group Hits New 52-Week High at $9.99
Lifestance Health Group, Inc. has achieved a new 52-week high, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. With a market capitalization of USD 2,463 million, the company has demonstrated significant growth, including a remarkable net profit increase and solid financial metrics, indicating a robust market position.
Lifestance Health Group Hits New 52-Week High of $9.54
Lifestance Health Group, Inc. has achieved a new 52-week high, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector with a notable annual increase. The company boasts a market capitalization of USD 2,463 million, low debt-to-equity ratio, and impressive growth metrics, including significant net profit growth and consistent positive quarterly results.
Lifestance Health Group Hits New 52-Week High at $9.11
Lifestance Health Group, Inc. has achieved a new 52-week high, reflecting strong performance with a significant increase over the past year. The company reported impressive financial metrics, including substantial net profit growth and positive operating cash flow, while maintaining a low debt-to-equity ratio and high institutional holdings.
Lifestance Health Stock Hits Day High with 9.54% Surge
Lifestance Health Group, Inc. has experienced notable market activity, achieving significant gains over various timeframes. The company reported impressive financial metrics, including substantial net profit growth and strong operating cash flow, while maintaining solid fundamentals and high institutional ownership.
Lifestance Health Stock Soars 25.5%, Hits Intraday High of $6.36
Lifestance Health Group, Inc. has seen notable stock activity, rising significantly today and over the past week. Despite recent positive quarterly results and strong institutional holdings, the company has struggled with long-term performance, showing a decline over the past year compared to the broader market.
Is Lifestance Health Group, Inc. technically bullish or bearish?
As of October 31, 2025, Lifestance Health Group, Inc. is in a bearish trend with weak strength indicators, having underperformed the S&P 500 significantly with a year-to-date return of -32.43% compared to the index's 16.30%.
Lifestance Health Group, Inc. Experiences Revision in Stock Evaluation Amid Market Fluctuations
Lifestance Health Group, Inc. has recently revised its evaluation amid fluctuating market conditions. The stock has shown mixed technical indicators, with varying trends in momentum. Year-to-date, it has significantly underperformed compared to the S&P 500, reflecting challenges in maintaining competitiveness in the pharmaceuticals and biotechnology sector.
Is Lifestance Health Group, Inc. technically bullish or bearish?
As of October 31, 2025, Lifestance Health Group, Inc. is in a bearish trend with weak strength, underperforming the S&P 500 significantly, showing a year-to-date return of -33.24% compared to the S&P 500's 16.30%.
Is Lifestance Health Group, Inc. technically bullish or bearish?
As of October 31, 2025, Lifestance Health Group, Inc. is in a bearish trend with weak strength indicators, having underperformed the S&P 500 significantly with a year-to-date return of -33.51%.
Is Lifestance Health Group, Inc. technically bullish or bearish?
As of October 31, 2025, Lifestance Health Group, Inc. is in a bearish trend with weak strength, indicated by daily moving averages and bearish signals from Bollinger Bands and monthly MACD, while underperforming the S&P 500 with a year-to-date return of -33.51%.
Is Lifestance Health Group, Inc. technically bullish or bearish?
As of August 13, 2025, Lifestance Health Group, Inc. shows a mildly bearish trend, with mixed signals from moving averages and indicators, and a year-to-date return of -27.14% compared to the S&P 500's 12.22%.
Is Lifestance Health Group, Inc. overvalued or undervalued?
As of November 8, 2021, Lifestance Health Group, Inc. is considered a risky investment due to its overvaluation, negative P/E ratio, poor returns on capital, and significant underperformance compared to the S&P 500.
Is Lifestance Health Group, Inc. overvalued or undervalued?
As of November 8, 2021, Lifestance Health Group, Inc. is rated as "risky" and overvalued, with a Price to Book Value of 1.56, an EV to EBITDA of 49.80, a negative ROE of -2.24%, and a year-to-date stock return of -32.7%, significantly underperforming the S&P 500's 2.44%.
Is Lifestance Health Group, Inc. technically bullish or bearish?
As of June 13, 2025, Lifestance Health Group, Inc. is in a bearish trend with moderate strength, indicated by bearish MACD readings, moving averages, and a significant underperformance of -32.7% year-to-date compared to the S&P 500's 2.44%.
What does Lifestance Health Group, Inc. do?
Lifestance Health Group, Inc. is a small-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $333 million and a net profit of $1 million as of March 2025. Key metrics include a market cap of $1.96 billion, a debt-to-equity ratio of 0.14, and a return on equity of -2.24%.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
